The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Jun. 9, 7:24 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #8. Prestige Brands Insight Pharmaceuticals

Acquirer: Prestige Brands (NYSE:PBH)
Acquiree: Insight Pharmaceuticals
Details: Prestige Brands Holdings, Inc.("Prestige" or the "Company") (NYSE:PBH) today announced that it has entered into a definitive agreement to acquire Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other over-the-counter ("OTC") healthcare products, for $750 million in cash. As part of the transaction, Prestige will acquire tax attributes with a present value of approximately $100 million, which results in an effective purchase price of approximately $650 million. This transaction, combined with the Hydralyte transaction announced on April 15, 2014, is expected to result in pro forma revenues and adjusted EBITDA of approximately $800 million and $300 million, respectively for the Company in fiscal 2015.

Prestige Consumer Healthcare is a holding company. Through its subsidiaries, Co. is engaged in the development, manufacturing, marketing, sales, and distribution of over-the-counter (OTC) health and personal care products. Co. conducts its operations in two reportable segments: North American OTC Healthcare and International OTC Healthcare. Co.'s brands in the North American OTC Healthcare segment include Boudreaux's Butt Paste baby ointments with products that include various diaper rash treatments and skin protectants. Co.'s brands in the International OTC Healthcare segment include Fess nasal saline sprays and washes.

PBH SEC Filing Email Alerts Service

Open the PBH Page at The Online Investor »

Company Name: 
Prestige Consumer Healthcare Inc
Stock buyback: 
PBH buyback
Drugs & Pharmaceuticals
Number of ETFs Holding PBH: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the PBH Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree PBH Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.33 out of 4)
46th percentile
(ranked lower than approx. 54% of all stocks covered)

Analysts' Target Price:
PBH Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 8 of 100 Page |

Copyright © 1998 - 2023, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.